Date: 2011-10-10
Type of information: Distribution agreement
Compound: ChondroCelect®
Company: Tigenix (Belgium) Finnish Red Cross Blood Service (Finland)
Therapeutic area: Rheumatic diseases
Type agreement: distribution
Action mechanism:
Disease: single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults with or without concomitant asymptomatic cartilage lesions (ICRS grade I or II).
Details: TiGenix and the Finnish Red Cross Blood Service (FRCBS) have signed an exclusive agreement for the distribution ChondroCelect® in Finland. Under the terms of the agreement, the FRCBS will facilitate patients\' access to ChondroCelect® in Finland by organising local regulatory approvals as a tissue establishment and pharma distribution specialist and providing training and product support to surgeons and healthcare professionals in selected orthopaedic centres. TiGenix is the marketing authorization holder and will be responsible for logistics and the manufacturing of ChondroCelect®.
Financial terms:
Latest news:
